Inhibition of miR-154 Protects Against Cardiac Dysfunction and Fibrosis in a Mouse Model of Pressure Overload

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Bernardo, Bianca C ^a   Nguyen, Sally S ^a,b   Gao, Xiao Ming ^a   Tham, Yow Keat ^a,c   Ooi, Jenny Y Y ^a   Patterson, Natalie L ^a   Kiriazis, Helen ^a   Su, Yidan ^a   Thomas, Colleen J ^b   Lin, Ruby C Y ^d,e   Du, Xiao Jun ^a,c   McMullen, Julie R ^a,c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d Centre for Education and Research on Aging   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYCLIN DEPENDENT KINASE INHIBITOR 2B; LOCKED NUCLEIC ACID; MICRORNA; MIRN154 MICRORNA, MOUSE; OLIGONUCLEOTIDE;

ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; BIOSYNTHESIS; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; ECHOCARDIOGRAPHY; GENETICS; HEART VENTRICLE REMODELING; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LUNG FIBROSIS; MALE; MOUSE; PATHOLOGY;

ANIMALS; AORTA; ATRIAL NATRIURETIC FACTOR; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; NATRIURETIC PEPTIDE, BRAIN; OLIGONUCLEOTIDES; PULMONARY FIBROSIS; VENTRICULAR REMODELING;

EID: 84959482106     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22442     Document Type: Article

References (42)

1. Braunwald, E. The war against heart failure: the Lancet lecture. The Lancet 385, 812-824 (2015).
2. Levy, D. et al. Long-term trends in the incidence of and survival with heart failure. N. Engl. J. Med. 347, 1397-1402 (2002).
3. Liu, L. & Eisen, H. J. Epidemiology of Heart Failure and Scope of the Problem. Cardiol. Clin. 32, 1-8 (2014).
4. Lin, R. C. Y. et al. PI3K(p110a) protects against myocardial infarction-induced heart failure/Identification of PI3K-regulated miRNAs and mRNAs. Arterioscler. Thromb. Vasc. Biol. 30, 724-732 (2010).
5. McMullen, J. R. et al. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc. Natl. Acad. Sci. USA 104, 612-617 (2007).
6. Pretorius, L. et al. Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. Am. J. Pathol. 175, 998-1009 (2009).
7. Ritchie, R. H. et al. Enhanced phosphoinositide 3-kinase(p110alpha) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes. Diabetologia 55, 3369-3381 (2012).
8. Weeks, K. L. et al. Phosphoinositide 3-kinase p110alpha is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction. Circ. Heart Fail. 5, 523-534 (2012).
9. Bernardo, B. C., Charchar, F. J., Lin, R. C. Y. & McMullen, J. R. A MicroRNA Guide for Clinicians and Basic Scientists: Background and Experimental Techniques. Heart, Lung and Circulation 21, 131-142 (2012).
10. Bernardo, B. C., Ooi, J. Y., Lin, R. C. & McMullen, J. R. miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart. Future Med Chem 7, 1751-1769 (2015).
11. Winbanks, C. E., Ooi, J. Y., Nguyen, S. S., McMullen, J. R. & Bernardo, B. C. MicroRNAs differentially regulated in cardiac and skeletal muscle in health and disease: Potential drug targets? Clin. Exp. Pharmacol. Physiol. 41, 727-737 (2014).
12. Hata, A. Functions of MicroRNAs in Cardiovascular Biology and Disease. Annu. Rev. Physiol. 75, 69-93 (2013).
13. Leite-Moreira, A. M., Lourenco, A. P., Falcao-Pires, I. & Leite-Moreira, A. F. Pivotal role of microRNAs in cardiac physiology and heart failure. Drug Discov. Today 18, 1243-1249 (2013).
14. Kumarswamy, R. & Thum, T. Non-coding RNAs in Cardiac Remodeling and Heart Failure. Circ. Res. 113, 676-689 (2013).
15. Bernardo, B. C. et al. Silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy. PLoS ONE 9, e90337 (2014).
16. Bernardo, B. C. et al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc. Natl. Acad. Sci. USA 109, 17615-17620 (2012).
17. Bernardo, B. C. et al. Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy. FASEB J. 28, 5097-5110 (2014).
18. Hullinger, T. G. et al. Inhibition of miR-15 Protects Against Cardiac Ischemic Injury/Novelty and Significance. Circ. Res. 110, 71-81 (2012).
19. Janssen, H. L. et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368, 1685-1694 (2013).
20. Milosevic, J. et al. Profibrotic role of miR-154 in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 47, 879-887 (2012).
21. Leask, A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ. Res. 106, 1675-1680 (2010).
22. Thannickal, V. J., Zhou, Y., Gaggar, A. & Duncan, S. R. Fibrosis: ultimate and proximate causes. J. Clin. Invest. 124, 4673-4677 (2014).
23. Thum, T. Noncoding RNAs and myocardial fibrosis. Nat. Rev. Cardiol. 11, 655-663 (2014).
24. Akhmetshina, A. et al. Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nat. Commun. 3, 735 (2012).
25. Koitabashi, N. et al. Pivotal role of cardiomyocyte TGF-beta signaling in the murine pathological response to sustained pressure overload. J. Clin. Invest. 121, 2301-2312 (2011).
26. Nishida, K., Taneike, M. & Otsu, K. The role of autophagic degradation in the heart. J. Mol. Cell. Cardiol. 78, 73-79 (2015).
27. Hutchinson, K. R., Stewart, J. A., Jr. & Lucchesi, P. A. Extracellular matrix remodeling during the progression of volume overloadinduced heart failure. J. Mol. Cell. Cardiol. 48, 564-569 (2010).
28. Yanagida, A. et al. Downregulation of the Wnt antagonist Dkk2 links the loss of Sept4 and myofibroblastic transformation of hepatic stellate cells. Biochim. Biophys. Acta 1812, 1403-1411 (2011).
29. Noda, S. et al. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. Nat. Commun. 5, 5797 (2014).
30. Husain-Syed, F. et al. Cardio-Pulmonary-Renal Interactions: A Multidisciplinary Approach. J. Am. Coll. Cardiol. 65, 2433-2448 (2015).
31. Skommer, J. et al. Small molecules, big effects: the role of microRNAs in regulation of cardiomyocyte death. Cell Death Dis. 5, e1325 (2014).
32. van Rooij, E. et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl. Acad. Sci. USA 103, 18255-18260 (2006).
33. Pottier, N., Cauffiez, C., Perrais, M., Barbry, P. & Mari, B. FibromiRs: translating molecular discoveries into new anti-fibrotic drugs. Trends Pharmacol. Sci. 35, 119-126 (2014).
34. Roubille, F. et al. Investigational drugs targeting cardiac fibrosis. Expert Rev. Cardiovasc. Ther. 12, 111-125 (2014).
35. Tham, Y. K., Bernardo, B. C., Ooi, J. Y., Weeks, K. L. & McMullen, J. R. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch. Toxicol. 89, 1401-1438 (2015).
36. Bhuiyan, M. S. et al. Enhanced autophagy ameliorates cardiac proteinopathy. J. Clin. Invest. 123, 5284-5297 (2013).
37. Olive, V., Jiang, I. & He, L. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int. J. Biochem. Cell Biol. 42, 1348-1354 (2010).
38. Murphy, B. L. et al. Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression. Cancer Res. 73, 7068-7078 (2013).
39. Formosa, A. et al. MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene 33, 5173-5182 (2014).
40. Rockey, D. C., Bell, P. D. & Hill, J. A. Fibrosis - A Common Pathway to Organ Injury and Failure. N. Engl. J. Med. 372, 1138-1149 (2015).
41. Foppa, M., Duncan, B. B. & Rohde, L. E. P. Echocardiography-based left ventricular mass estimation. How should we define hypertrophy? Cardiovasc. Ultrasound 3, 17 (2005).
42. Leptidis, S. et al. A deep sequencing approach to uncover the miRNOME in the human heart. PLoS ONE 8, e57800 (2013).